luPSMA randomised control trial good early results

[street-air]

youtube.com/watch?v=S_JvSVl...(Not working as expected?)

thelancet.com/journals/lano...

Some phase 2 early results : adding LuPSMA to (ADT + docetaxel) has generated a strong result in men with "newly diagnosed high-volume mHSPC"

April 2020 the trial started.

" 25 (41%) of 61 patients (95% CI 30–54) in the [177Lu]Lu-PSMA-617 plus docetaxel group had undetectable PSA at 48 weeks compared with ten (16%) of 61 patients (9–28) in the docetaxel alone group (OR 3·88, 95% CI 1·61–9·38; p=0·0020). "

The patients were selected for the trial if they had high PSA and PSMA expression. A surprising number of patients initially selected were rejected for "discordant" application ( supposedly high volume cancer, but found to have low PSMA expression or low PSA due to initial ADT, or very heterogeneous disease ).